Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.

Ken KoshikawaJiro TeradaMitsuhiro AbeShunichiro IwasawaMasashi SakayoriKeiichiro YoshiokaYasutaka HirasawaHajime KasaiYohei KawasakiKenji TsushimaKoichiro Tatsumi

Published in: Thoracic cancer (2020)

The same or a different ALK-TKI may be considered as a treatment option after the onset of DILI, based on careful judgment.

Keyphrases

drug induced
liver injury
advanced non small cell lung cancer
risk factors
chronic myeloid leukemia
tyrosine kinase
adverse drug
epidermal growth factor receptor
combination therapy